A somatic point mutation in the tyrosine kinase JAK2 (1849 G to T) has been described in myeloproliferative diseases (MPD), resulting in a non-synonymous amino-acid substitution (V to F) at position 617. This mutation (JAK2V617F) is located in the JH2 pseudo-kinase auto-inhibitory domain, rendering the enzyme constitutively active and leading to cytokine hypersensitivity and erythrocytosis in mice. 1 There is considerable variation in the reports of JAK2V617F frequency in MPD, with incidence rates of 23-57% in essential thrombocythemia, 35-57% in idiopathic myelofibrosis and 65-97% in polycythemia vera (PV). 2 Of particular interest is the expression of JAK2V617F mutation in PV, with its hallmark of erythrocytosis, which involves the JAK2-signaling pathway. Possible reasons for discrepancies in the observed mutation frequency in PV by different research groups include (1) differences in assay sensitivity, 3 (2) diagnostic inaccuracy and (3) treatment effect. 4 In order to examine these possibilities, we have re-examined 17 previously published JAK2V617F-negative PV cases, including nine from the Mayo Clinic, 5, 6 four from the MD Anderson Cancer Center (MDACC) 7 and four from the Weill Medical College. 8 Among the nine Mayo Clinic cases, the diagnosis was inaccurate in four and questionable in one. Repeat testing with more sensitive techniques revealed the presence of the mutation in three of the remaining four patients. In the last patient, there was not enough material for re-testing. Among the four MDACC cases, two were positive for JAK2V617F mutation on re-testing using a more sensitive technique; mutation screening in the other two patients was performed at the time of leukemic transformation and the historical diagnosis of PV had not been well documented. Of the four cases reported by the Weill Medical College researchers, two were receiving interferon-a therapy for several years before testing for the mutation, and two had interferon discontinued 2 years before testing for JAK2 because of excellent clinical response. Thus, treatment could have resulted in the suppression of the mutant clone. 4 Therefore, we conclude that a diagnosis of 'PV' in the absence of the JAK2V617F warrants a re-evaluation that takes into account the possibility for misdiagnosis, treatment-related effect and an insufficiently sensitive mutation screening assay. Once these three issues are addressed, it seems likely that the JAK2V617F mutation may be present in virtually all PV patients. Activation of tyrosine kinase pathways has been implicated in the pathogenesis of myeloproliferative disorders (MPD).
Recently, a point mutation of the cytoplasmic Janus kinase 2 (JAK2) has been identified in MPD, including polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). JAK2 V617F is a somatic mutation present in hematopoietic cells that leads to constitutive activation of the JAK2 tyrosine kinase and phosphorylation of STAT5. Expression
Letters to the Editor of the JAK2 V617F kinase in vitro leads to factor-independent growth. 1, 2 In addition, expression of JAK2 V617F in a murine bone marrow transplant model results in erythrocytosis in recipient mice.
1 JAK2 V617F mutation was detected by several groups in most PV patients (90%) and in approximately 40% of ET and 50% of IMF patients. [1] [2] [3] [4] These data suggest that JAK2 V617F mutation is likely to contribute to the development of MPD and, therefore, may be one diagnostic tool for the identification of MPD. JAK2 V617F mutation also occurs in other myeloid malignancies, such as Philadelphia chromosomenegative chronic myeloid leukemia (atypical CML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), but it is relatively infrequent in these diseases compared to the three classic BCR-ABL-negative MPD. 5 The recent World Health Organization (WHO) classification recognizes a separated category of myeloid disorders that overlaps traditional MDS and MDP as the entity MDS/MPD. This hybrid group comprises four subtypes: CMML, juvenile myelomonocytic leukemia, atypical CML and unclassifiable MDS/MPD, including MDS with thrombocytosis 4600 G/l, common feature of MPD. For this reason, refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) has been categorized as unclassifiable MDS/MPD, until further information is available regarding its pathogenesis. 6 Appropriate classification for RARS-T remains a matter of debate.
Recently, two groups independently reported several cases of RARS-T harboring JAK2 V617F mutation. Altogether, nine of the 12 cases published so far were JAK2 mutants. 7, 8 To confirm these findings, we explored the JAK2 mutational status in seven RARS-T patients. JAK2 V617F mutation had been initially detected in three RARS-T patients for diagnostic purpose, from October 2005 to March 2006. To increase the number of cases, we subsequently recruited another four patients with RARS-T diagnosed before this period and for whom frozen cells were available. DNA from peripheral blood samples collected at the time of diagnosis was obtained for each of these seven patients. Samples from 15 patients with CMML, 42 patients with MDS, nine patients with secondary AML following a preceding MDS and 290 patients with typical BCR-ABL-negative MPD were also screened for JAK2 mutation as hematologic controls. Informed consent was obtained from all patients to use their samples for molecular analysis. JAK2 V617F mutation was detected by single-nucleotide polymorphism genotyping assays using realtime polymerase chain reaction (PCR)-based mutation detection (TaqMan ABI PRISM 7000), as described by James et al. 9 All analyses were performed in duplicate. The data were processed using Sequence Detection Software 1.2.3. The sensitivity of this PCR assay is about 2-4% of a homozygously mutated patient DNA diluted in normal DNA.
JAK2 V617F mutation was identified in 78/148 (53%) patients with ET, 86/92 (93%) patients with PV and 30/50 (60%) patients with IMF, as already reported by different teams. [1] [2] [3] [4] Among 42 MDS patients, one (2%) with refractory anemia with excess of blasts 2 was JAK2 mutant. JAK2 V617F mutation was also found in 1/9 (11%) patients with secondary AML following a preceding MDS and 2/15 (13%) patients with CMML. Strikingly, five of seven (71%) RARS-T patients had JAK2 V617F mutation at initial presentation (Table 1 ). This result was very similar to the frequency reported by Szpurka et al. 8 (67%). Although the prevalence of JAK2 mutation in RARS-T should be confirmed in a larger cohort of patients, these data suggest that the prevalence of JAK2 V617 mutation in RARS-T is relatively high and comparable with classic MPD (PV, ET and IMF).
We then focused on RARS-T patients and analyzed their main clinical and laboratory features ( Table 2) . Among the seven RARS-T patients studied, no signs of MPD (splenomegaly, leukocytosis, myelemia) were present at initial diagnosis apart from marked thrombocytosis. All patients exhibited platelet counts X600 G/l. No causes of reactive thrombocytosis (iron deficiency, inflammation, post splenectomy state) were found. No thrombotic event has occurred in the RARS-T group during the follow-up period. All patients had moderate anemia associated with elevation of mean corpuscular volume in 3/7 cases. Bone marrow morphologic analysis showed normal or hypercellularity. The number of megakaryocytes was found increased in four cases and normal in others. The majority of patients presented no significant signs of dysmegakaryopoiesis, especially no enlarged and clustered megakaryocytes, as described previously. 7, 8, 10 One patient had small-sized megakaryocytes and another megakaryocytes with hypolobulated or widely separated nuclei. None of them harbored the typical megakaryocytes morphology of 5qÀ syndrome. Cytogenetic analysis revealed that all patients had normal karyotype at the time of diagnosis, except one who had del(11q). Hypogranulation was seen in 4/7 patients. Bone marrow blasts percentage was o5% in all cases. A common feature of all RARS-T patients was mild or moderate dyserythropoiesis similar to RARS (megaloblastoid changes, asynchrony of nuclear-cytoplasmic maturation, basophil stippling and lacunar cytoplasm). Proportion of ringed sideroblasts was found to be 415% in all cases. Only one patient (n17) had a bone marrow biopsy at the time of diagnosis that revealed no evidence of MPD. Semisolid clonogenic assay of BFU-E, available for four RARS-T patients, showed an absence of endogenous erythroid colony formation without erythropoietin. Moreover, in three of four cases, colonies obtained with erythropoietin were quite rare and not well developed, probably in relation to erythroid dysplasia that Table 1 Mutational status in RARS-T patients and in hematologic controls Refractory anemia with excess of blasts in transformation (RAEB-T) in the French-American-British classification.
Letters to the Editor exists in refractory anemia. Interestingly, one patient (n11) evolved to IMF with appearance of erythromyelemia and circulating blasts, development of splenomegaly and acquisition of a cytogenetic abnormality (del(Y)). Another patient (n12) transformed to AML after 10 years evolution and died shortly after. Other patients were still alive at last follow-up with no signs of progression of their hematological disease. According to Shaw, 10 RARS-T and RARS patients had very similar median survival (71 versus 64 months, respectively) and this median survival was less favorable than ET.
Thrombocytosis has been classically associated with some MDS subtypes, including RARS, 5qÀ syndrome and MDS with 3q chromosome abnormalities. Besides, thrombocytosis and ringed sideroblasts can also be found in patients with 5q-syndrome. 10 RARS-T is considered as a provisional entity that belongs to the unclassifiable MDS/MPD category in the WHO classification.
6 RARS-T seems to be an overlap between MPD and MDS that shares features of both MPD (thrombocytosis, abnormal megakaryocytes, evolution to IMF, high frequency of JAK2 V617F mutation) and MDS (macrocytic anemia, dyserythropoiesis, ringed sideroblasts). 7, 8, 10 More restrictive diagnostic criteria for RARS-T have been proposed by Shaw in 2005. Positive diagnostic criteria were (i) platelets counts 4500 G/l (46 months) and an increase in bone marrow megakaryocytes with some giants forms, (ii) bone marrow aspirate smear with 415% erythroid precursors being ringed sideroblasts and (iii) normal conventional cytogenetics study performed on the bone marrow.
10
JAK2 V617F constitutes an important genetic event in MPD, but is not specifically associated with classic MPD and may play a role in the pathogenesis of a wide spectrum of hematopoietic malignancies. However, high prevalence of JAK2 mutation has only been found in PV, ET and IMF. Consequently, the high occurrence of JAK2 V617F mutation in RARS-T indicates that the molecular basis of RARS-T is closely related to classic MPD and provides additional information to classify RARS-T as a mixed MDS/MPD syndrome. It still remains controversial whether RARS-T corresponds to two different simultaneous pathologies (RARS and ET) or, more likely, to a unique disease. Further studies are needed to investigate if one or two malignant clones are implicated. Thus, a more suitable characterization of this ambiguous category may help to define a more accurate prognosis and improve therapeutic management of these patients.
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Reciprocal chromosomal translocations are a hallmark of many B-cell lymphomas, and are frequently seen as recurrent abnormalities. As such, they appear to delineate specific subsets in individual lymphoma categories. Their occurrence also raises the question whether they might associate with distinct pathways of clonal origins or tumor behavior. The reciprocal translocations that juxtapose immunoglobulin (Ig) gene loci and proto-oncogenes are of particular interest, as they result in upregulated proto-oncogene expression, owing to translocated Ig enhancer elements. These types of translocations are important in diffuse large B-cell lymphoma (DLBCL), a disease that displays marked heterogeneity in presentation and outcome. Of note, the t(14;18)(q32;q21) and t(3;14)(q27;q32) translocations are two of the most frequent translocations observed in DLBCL. They dysregulate expression of the antiapoptotic protein BCL2, or the germinal center (GC) transcription factor BCL6, respectively, and it is thought that aberrant expression of these molecules may initiate distinctive pathogenetic mechanisms. 1 In order to track how defined chromosomal abnormalities may associate with specific tumor origins in DLBCL, investigators have recently begun to exploit insights emerging from gene expression profiles. 2 These profiles provide a means of classifying disease heterogeneity in DLBCL, and have defined three distinct tumor subtypes that have a prognostic and biological relevance. 2 The germinal center-B cell like (GCB) subset is characterized by an expression profile resembling that of normal GC B-cells. The activated-B-cell-like (ABC) profile is characterized by expression of genes normally induced during in vitro activation of B-cells, and Type 3 profiles represent expression of heterogeneous GCB or ABC genes. 2 In order to simplify the methodological requirement for identification of GC/non-GCB signatures in DLBCL, Hans et al. have established a cohort of genes that can be evaluated by immunohistochemistry (IHC). 3 They have shown that the IHC criteria can achieve a GC/non-GCB designation that is able to predict survival as well as complementary DNA microarray profiles. Classification of DLBCL with t(14;18)(q32;p21) or t(3;14)(q27;q32) by immunohistochemical criteria into GCB or non-GCB subtypes according to the algorithm proposed by Hans et al. 
